1. "Whether the district court legally erred in its framework for evaluating objective indicia of non-obviousness, by (a) concluding that the claims were obvious before even analyzing the compelling objective indicia...
"Whether the district court erred in holding that any reasonable juror was required to find that Sanofi-Regeneron established non-enablement by clear-and- convincing evidence."
1. "Whether the Court should vacate the district court’s judgment of noninfringement by Watson and direct entry of the consent judgment necessary to effectuate the parties’ agreement to settle, because:...
1. “Is Bio-Rad barred as a matter of law from asserting infringement under the doctrine of equivalents where it amended its claims to exclude the very terrain it now accuses,...
1. "Whether the asserted claims are invalid because: (1) They were anticipated by the prior art; or (2)They are not enabled and lack sufficient written description."
2. "Whether the asserted claims...
1. "Whether the CFC erred in holding that a NITU—which did not authorize third-party use of the railroad’s right-of-way but merely imposed a short administrative hold in the railroad’s voluntary...
1. "Whether, in determining that Patent No. 6,477,151 (the ‘151', or the '’151 Patent') is unenforceable, the district court committed an error of law in failing to apply a 'but...
"Whether substantial evidence supports the jury’s verdict that Teva willfully induced infringement of GSK’s patented method of treating congestive heart failure where: (a) Teva encouraged the infringing use in promotional...
1. "Whether the CFC erred in ruling that a number of deeds for the rail corridor at issue in this case conveyed merely an easement to the railroad where no...
1. "Whether the patents-in-suit are invalid for [obviousness-type double patenting], where Immunex— which owns all substantial rights in those patents, including the ability to control patent prosecution—had already obtained earlier-expiring...
1. "Whether Arthrex should be extended to ex parte examination cases."
2. "Whether the Director’s purported ability to refuse to issue a patent if the Patent Trial and Appeal Board approves...
1. "Did the CAVC misinterpret Rule 23(a)’s commonality requirement to require that a proposed class of disabled veterans seeking class certification of claims alleging unreasonable system-wide delay always identify a...
"Congress has conferred limited authority on the judiciary to charge fees for access to electronic court records. These fees may be imposed 'as a charge for services rendered' to 'reimburse...
"I. Network-1’s Appeal
A. Independent Basis for Verdict: Does the evidence compel a finding of non-infringement irrespective of the challenged constructions?
B. Claim Construction:
1. Did the district court properly...
1. "Whether the insurers’ statutory claims fail because Congress did not intend for insurers to receive damages as compensation for cost-sharing payments that Congress declined to fund."
2. "Whether the insurers’...
"Whether a claimant’s general statement requesting benefits on a formal claim form that identifies specific disabilities constitutes a claim for all 'reasonably identifiable' diagnoses within the claimant’s records."
1. "Section 1.2(d) of the License Agreement at issue in this case permits Alkem to launch its generic Colcrys® product a specified time period 'after the date of a Final...
1. "Section 1.2(d) of the License Agreement at issue in this case permits Mylan to launch its generic colchicine product a specified time period 'after the date of a Final...
1. "Did the district court err in concluding that it cannot exercise personal jurisdiction over PerDiemCo even though (a) PerDiemCo expressly and repeatedly accused Trimble, a company based in northern...
"The primary issue on appeal is whether the Board erred in denying, based only on a § 101 patent eligibility challenge, Uniloc’s motion to amend the patent in this inter...
